AromaDb: A Database of Plant's Aroma Molecules

Acetylformic acid Details

: IUPAC Name
Pyruvicacid
:Chemical Class
:CAS Registry Number
127-17-3
:Description

:Fragrance Type
sour vinegar

Physical and Chemical properties

PUBCHEM ID1060
Molecular Weight (mg/mol)88.065
Molecular FormulaC3H4O3
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count2
Rotatable Bond Count1
IUPAC NamePyruvicacid
Canonical SMILESCC(=O)C(=O)O
PUBCHEM IUPAC INCHIKEYLCTONWCANYUPML-UHFFFAOYSA-N
Solubility Level5
Vapour Pressure-0.367

Absorption and Metabolism information

XLOGP3 AANA
CACTVS TPSA43.09
BBB Level3
Absorption Level0
EXT PPB#Prediction0
AlogP98-0.329
EXT CYP2D6#Prediction0

Toxicological Information

Mouse Female FDAMulti-Carcinogen
Mouse Male FDAMulti-Carcinogen
Rat Female FDASingle-Carcinogen
Rat Male FDAMulti-Carcinogen
Ames PredictionNon-Mutagen
Developmental / Reproductive ToxicityToxic
Rat Oral LD501.07703
Ocular IrritancySevere
Hepatotoxic#Prediction1
Effected Human GenesNA

Ecological Information

Aerobic Biodegradability PredictionDegradable

Hazard(s) Identification

Physical hazardsnot classified
Health hazards Mild
Environmental hazardsnot classified
About Table Headings

Compound Biological Activity

Serial No.Cas No Gene SymbolOrganismInteraction Interaction ActionsPubMed Id
1 127-17-3 ACACA Homo sapiens [Pyruvic Acid co-treated with Glucose] results in increased phosphorylation of ACACA protein affects^cotreatment|increases^phosphorylation 19071085
2 127-17-3 ADRB3 Mus musculus [BRL 37344 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Pyruvic Acid affects^binding|increases^abundance|increases^activity 20930473
3 127-17-3 ATP5A1 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of ATP5A1 protein affects^cotreatment|increases^expression 25997894
4 127-17-3 BECN1 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in decreased expression of BECN1 protein] affects^cotreatment|decreases^expression|decreases^reaction 25997894
5 127-17-3 CASP3 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] affects^cotreatment|decreases^reaction|increases^activity 25997894
6 127-17-3 CASP9 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased activity of CASP9 protein] affects^cotreatment|decreases^reaction|increases^activity 25997894
7 127-17-3 COX1 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of COX1 protein affects^cotreatment|increases^expression 25997894
8 127-17-3 CTBP1 Homo sapiens Pyruvic Acid inhibits the reaction [CTBP1 protein binds to CTBP2 protein] affects^binding|decreases^reaction 18184656
9 127-17-3 CTBP1 Homo sapiens Pyruvic Acid inhibits the reaction [CTBP1 protein binds to NR5A1 protein] affects^binding|decreases^reaction 18184656
10 127-17-3 CTBP1 Homo sapiens Pyruvic Acid promotes the reaction [CTBP1 protein binds to CYP17A1 promoter] affects^binding|increases^reaction 18184656
11 127-17-3 CTBP2 Homo sapiens Pyruvic Acid promotes the reaction [CTBP2 protein binds to CYP17A1 promoter] affects^binding|increases^reaction 18184656
12 127-17-3 CYP17A1 Homo sapiens Pyruvic Acid promotes the reaction [NR5A1 protein binds to CYP17A1 promoter] affects^binding|increases^reaction 18184656
13 127-17-3 CYP17A1 Homo sapiens Pyruvic Acid results in increased expression of CYP17A1 mRNA increases^expression 18184656
14 127-17-3 CYP3A11 Mus musculus Pyruvic Acid inhibits the reaction [PPARGC1A protein promotes the reaction [Pregnenolone Carbonitrile results in increased expression of CYP3A11 mRNA]] decreases^reaction|increases^expression|increases^reaction 21933665
15 127-17-3 CYP3A11 Mus musculus SIRT1 mRNA affects the reaction [Pyruvic Acid inhibits the reaction [PPARGC1A protein promotes the reaction [Pregnenolone Carbonitrile results in increased expression of CYP3A11 mRNA]]] affects^reaction|decreases^reaction|increases^expression|increases^reaction 21933665
16 127-17-3 IL4 Rattus norvegicus Pyruvic Acid inhibits the reaction [Mercuric Chloride results in increased expression of IL4 mRNA] decreases^reaction|increases^expression 11222498
17 127-17-3 KCNH2 Homo sapiens Pyruvic Acid inhibits the reaction [[Deoxyglucose co-treated with Glucose deficiency] results in decreased activity of KCNH2 protein] affects^cotreatment|decreases^activity|decreases^reaction 12531891
18 127-17-3 ME1 Columbidae [Pyruvic Acid co-treated with manganese chloride] promotes the reaction [NADP binds to ME1 protein] affects^binding|affects^cotreatment|increases^reaction 7356971
19 127-17-3 NDUFB8 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of NDUFB8 protein affects^cotreatment|increases^expression 25997894
20 127-17-3 PDK4 Mus musculus [PDK4 affects the abundance of Pyruvic Acid] which results in increased expression of SIRT1 affects^abundance|increases^expression 21182459
21 127-17-3 PPARGC1A Homo sapiens [Pyruvic Acid co-treated with Glucose] results in decreased acetylation of PPARGC1A protein affects^cotreatment|decreases^acetylation 19071085
22 127-17-3 PRNP Ovis aries Pyruvic Acid inhibits the reaction [Peroxynitrous Acid results in decreased activity of PRNP protein] decreases^activity|decreases^reaction 14713301
23 127-17-3 SIRT1 Homo sapiens [Glucose deficiency co-treated with Galactose co-treated with Amino Acids co-treated with Pyruvic Acid] inhibits the reaction [resveratrol results in increased expression of SIRT1 protein] affects^cotreatment|decreases^reaction|increases^expression 27358235
24 127-17-3 SIRT1 Homo sapiens [Pyruvic Acid co-treated with Glucose] results in increased expression of and results in increased activity of SIRT1 protein affects^cotreatment|increases^activity|increases^expression 19071085
25 127-17-3 SIRT1 Mus musculus Pyruvic Acid results in increased expression of SIRT1 mRNA increases^expression 21933665
26 127-17-3 SLC2A4 Mus musculus Pyruvic Acid inhibits the reaction [Palmitates results in decreased expression of SLC2A4 mRNA] decreases^expression|decreases^reaction 21802492
27 127-17-3 SOD1 Homo sapiens Pyruvic Acid inhibits the reaction [SOD1 protein mutant form results in increased susceptibility to cupric chloride] decreases^reaction|increases^response to substance 15812313
28 127-17-3 TFAM Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] results in increased expression of TFAM protein affects^cotreatment|increases^expression 25997894
29 127-17-3 TP53 Rattus norvegicus [Glucose deficiency co-treated with Galactose co-treated with Pyruvic Acid] inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] affects^cotreatment|decreases^reaction|increases^expression 25997894
Serial No.Activity Name DetailsReferences (PubMed)Other details EPA (U.S)Clinical Trials (U.S. NIH)
1 127-17-3 Acetylformic acid

Compound Image


2D Structure

Download




Download Sdf File Download PDB File Download MOL File
View Similar Structures